CLSA Reiterates Buy (1) Rating on Cadila Healthcare (CDH:IN)
- S&P 500, Nasdaq open higher; Amex, Honeywell weigh on Dow
- No Surprises in President Biden's Reported Capital Gains Proposal, a 28% Rate Looks Most Likely - Goldman Sachs
- Bitcoin sinks below $50,000 as cryptos stumble over Biden tax plans
- Snap (SNAP) Beats Q1 Estimates Amid 'Robust Ad Environment,' Analysts Raise Numbers and PTs
- Intel (INTC) Tops Q1 EPS by 24c, Offers Guidance
CLSA analyst Alok Dalal reiterated a Buy (1) rating and INR580.00 price target on Cadila Healthcare (CDH:IN).
You May Also Be Interested In
- Cadila Healthcare (CDH:IN) PT Raised to INR525 at HSBC
- Mullen Group (MTL:CN) (MLLGF) PT Raised to Cdn$15 at RBC Capital
- Gildan Activewear (GIL:CN) (GIL) PT Raised to $35 at RBC Capital
Create E-mail Alert Related CategoriesIntl Ratings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!